Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

被引：0
|
作者：
Yali Yi
Jing Cai
Peng Xu
Le Xiong
Zhiqin Lu
Zhimin Zeng
Anwen Liu
机构：
[1] The Second Affiliated Hospital of Nanchang University,Department of Oncology
[2] The Second Affiliated Hospital of Nanchang University,Jiangxi Key Laboratory of Clinical Translational Cancer Research
来源：
Journal of Translational Medicine | / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
    Yali Yi
    Jing Cai
    Peng Xu
    Le Xiong
    Zhiqin Lu
    Zhimin Zeng
    Anwen Liu
    Journal of Translational Medicine, 20
  • [2] Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
    Yi, Yali
    Cai, Jing
    Xu, Peng
    Xiong, Le
    Lu, Zhiqin
    Zeng, Zhimin
    Liu, Anwen
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [3] Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer (vol 20, 122, 2022)
    Yi, Yali
    Cai, Jing
    Xu, Peng
    Xiong, Le
    Lu, Zhiqin
    Zeng, Zhimin
    Liu, Anwen
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [4] Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis
    Chiang, Chi-Lu
    Ho, Hsiang-Ling
    Yeh, Yi-Chen
    Lee, Cheng-Chia
    Huang, Hsu-Ching
    Shen, Chia-, I
    Luo, Yung-Hung
    Chen, Yuh-Min
    Chiu, Chao-Hua
    Chou, Teh-Ying
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (01) : 5 - 14
  • [5] Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis
    Chi-Lu Chiang
    Hsiang-Ling Ho
    Yi-Chen Yeh
    Cheng-Chia Lee
    Hsu-Ching Huang
    Chia-I Shen
    Yung-Hung Luo
    Yuh-Min Chen
    Chao-Hua Chiu
    Teh-Ying Chou
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5 - 14
  • [6] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [7] Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
    Okuma, Yusuke
    Nomura, Shogo
    Ninomiya, Kiichiro
    Gyotoku, Hiroshi
    Murakami, Shuji
    Kogure, Yoshihito
    Harada, Daijiro
    Okishio, Kyoichi
    Okamoto, Hiroaki
    Goto, Yasushi
    FUTURE ONCOLOGY, 2023, : 1515 - 1521
  • [8] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [9] Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
    Chiang, Chi-Lu
    Lee, Cheng-Chia
    Huang, Hsu-Ching
    Wu, Chia-Hung
    Yeh, Yi-Chen
    Shen, Chia-, I
    Luo, Yung-Hung
    Shiao, Tsu-Hui
    Chang, Han Jhih
    Huang, Yu-Ting
    Chen, Yuh-Min
    Chou, Teh-Ying
    Chiu, Chao-Hua
    TARGETED ONCOLOGY, 2021, 16 (02) : 207 - 214
  • [10] Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
    Chi-Lu Chiang
    Cheng-Chia Lee
    Hsu-Ching Huang
    Chia-Hung Wu
    Yi-Chen Yeh
    Chia-I Shen
    Yung-Hung Luo
    Tsu-Hui Shiao
    Han Jhih Chang
    Yu-Ting Huang
    Yuh-Min Chen
    Teh-Ying Chou
    Chao-Hua Chiu
    Targeted Oncology, 2021, 16 : 207 - 214
12345